Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

ANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key ...

The beauty of this company is that its inhibition of C1q can be applied towards other ... file its BLA of this intravenous [IV] monoclonal antibody for the treatment of this patient population ...

The “classical” pathway of the complement system is triggered when C1q binds to antibodies that are already bound to antigens on a cell surface. It only comes into effect when a high number of ...

Anti-C1q antibodies were positive. Other tests, including the extractable nuclear antigens (ENA), anti-dsDNA, antineutrophil cytoplasmic antibodies (ANCA), rheumatoid factor, HLA-B27, hepatitis B and ...

Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) is a rare variant of monoclonal gammopathy of renal significance (MGRS). Although the pathogenesis of PGNMID is not ...

Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q antibodies and urinary erythrocytes have the best predictive power to dist ...

Anti-C1q antibodies are a promising marker for the diagnosis and management of lupus nephritis. Immunological tests can differentiate proliferative from non-proliferative lupus nephritis ...